Metabolic research peptides compared across a single catalog can be difficult to navigate, because compounds that look superficially similar often act on entirely different receptor systems. This overview maps the three principal families represented in the NeuroLabs metabolic catalog — incretin receptor agonists, amylin-receptor (amylinomimetic) peptides, and lipolytic/growth-hormone-axis fragments — so researchers can distinguish them by mechanism rather than by marketing category. The goal is orientation: understanding which pathway a given compound engages before designing an in-vitro or preclinical study.
Research Use Only. All compounds referenced here are supplied strictly for laboratory research use only. They are not for human or veterinary use, are not dietary supplements, and have not been evaluated by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Descriptions below concern receptor pharmacology and published preclinical findings, not therapeutic guidance.
Three Mechanistic Families in the Metabolic Catalog
Metabolic peptides studied in research models tend to cluster around a handful of signaling axes. Rather than grouping by intended outcome, it is more scientifically useful to group by the receptor each peptide binds. The NeuroLabs catalog spans three:
- Incretin receptor agonists — engage GLP-1, GIP, and/or glucagon receptors, all class B G-protein-coupled receptors (GPCRs) coupled to adenylate cyclase and cAMP signaling.
- Amylin-receptor agonists (amylinomimetics) — act at calcitonin-receptor complexes modified by RAMP co-proteins, a signaling route distinct from the incretin GPCRs.
- Lipolytic and GH-axis fragments — modulate lipid metabolism or growth-hormone signaling rather than glucose-dependent insulin pathways.
For a deeper primer on the incretin system specifically, see our GLP-1 in Research: Incretin Peptide Overview.
Family 1: Incretin Receptor Agonists
Incretin peptides are defined by their action on the class B GPCRs that govern glucose-dependent insulin secretion. The relevant distinction among them is how many receptors they engage.
Single and dual incretin agonists
Tirzepatide-class compounds are dual GIP/GLP-1 receptor agonists. In preclinical models, co-activation of the GIP and GLP-1 receptors has been examined for additive effects on cAMP accumulation and insulinotropic signaling relative to GLP-1-only agonism. The NeuroLabs NL-2 (Tirzepatide) 10–40mg is the catalog's representative dual-agonist reference compound. Research comparing it against other incretin agonists is discussed in NL-2 vs Retatrutide: Incretin Research Compared.
Triple incretin agonists
Retatrutide-class peptides extend agonism to a third receptor — the glucagon receptor — producing a GIP/GLP-1/glucagon triagonist. In research models the glucagon-receptor component has been studied for its influence on hepatic lipid handling and energy expenditure, mechanistically separate from the insulinotropic arm. The NL-3 (Retatrutide) 5–40mg serves as the triagonist reference. The mechanistic contrast between dual and triple agonism is the single most important axis separating NL-2 and NL-3 in a research context.
Family 2: Amylin-Receptor Agonists
Amylin (islet amyloid polypeptide) signals through calcitonin receptors complexed with receptor-activity-modifying proteins (RAMP1/2/3), forming the AMY1–3 receptor subtypes. This is a fundamentally different receptor family from the incretin GPCRs. Cagrilintide 5mg is a long-acting amylinomimetic used in research to probe amylin-receptor signaling and its interaction with incretin pathways.
Because amylin and incretin receptors are distinct, researchers frequently study them in combination to examine potential complementary or additive signaling. Two related comparisons cover this ground: Retatrutide vs Cagrilintide: Metabolic Research and Cagrilintide vs GLP-1 Agonists: Research Contrast.
Family 3: Lipolytic and GH-Axis Fragments
The third family does not touch the glucose-insulin axis directly. AOD-9604 5mg is a modified fragment of the C-terminus of human growth hormone (residues 176–191). In preclinical and in-vitro models it has been studied for effects on lipid metabolism that appear largely independent of GH-receptor-mediated growth signaling and of insulin sensitivity. This mechanistic separation is why lipolytic fragments occupy their own category rather than sitting alongside the incretins. A fuller treatment of fat-metabolism research peptides appears in AOD-9604 vs Tesamorelin: Fat-Research Compared.
Side-by-Side: Mechanism Map
| Compound | Family | Primary Receptor Target(s) | Signaling Route |
|---|---|---|---|
| NL-2 (Tirzepatide) | Incretin | GIP + GLP-1 receptors | Class B GPCR / cAMP (dual) |
| NL-3 (Retatrutide) | Incretin | GIP + GLP-1 + glucagon receptors | Class B GPCR / cAMP (triple) |
| Cagrilintide | Amylinomimetic | AMY1–3 (calcitonin + RAMP) | Calcitonin-receptor complex |
| AOD-9604 | Lipolytic fragment | hGH 176–191 fragment activity | Lipid-metabolism pathways |
Why the Mechanism Map Matters for Study Design
Grouping by receptor rather than by outcome has practical consequences for experimental work:
- Assay selection. Incretin agonists are typically characterized with cAMP-accumulation or β-arrestin recruitment assays against the relevant class B GPCRs. Amylinomimetics require calcitonin/RAMP co-expression systems. A lipolytic fragment assay looks different again.
- Cross-family combination studies. Because incretin and amylin receptors are independent, combination research models must control for each pathway separately.
- Reference compound choice. When benchmarking a novel analog, the appropriate reference is one from the same family — a dual agonist against NL-2, a triagonist against NL-3.
Laboratory Handling Notes
These are general handling considerations for lyophilized research peptides, not usage instructions. Reconstitution with bacteriostatic or sterile water and storage of the resulting solution refrigerated (2–8 C), with lyophilized powder kept frozen and protected from light, are standard for maintaining peptide integrity in the laboratory. Each NeuroLabs compound ships with a third-party Certificate of Analysis documenting ≥99% purity, and researchers should confirm identity and purity against the supplied COA before use.
Where to Go Next
For the broader framework tying these families together, return to the pillar overview: Metabolic & GLP Research Peptides. From there, the head-to-head comparisons drill into specific pairings across the incretin, amylin, and lipolytic families.
Reminder: every compound described is for laboratory research use only — not for human or veterinary use, not a supplement, and not evaluated by the FDA to diagnose, treat, cure, or prevent any disease.